Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?
Purpose of Review
Acute decompensated heart failure (ADHF) is one of the biggest challenges in the management of chronic heart failure. Despite several advances in medical and device therapy, high readmission and mortality rates continue to be a burden on healthcare systems worldwide. The aim of the current review is to provide an overview on current as well as future approaches in cardiorenal interactions in patients with ADHF.
One of the strongest predictors of adverse outcomes in ADHF is renal dysfunction, referred to as cardiorenal syndromes (CRS) or cardiorenal interactions. Patients with ADHF frequently develop worsening of renal function (WRF) and/or acute kidney injury (AKI). Recent studies brought new information about biomarkers in diagnosing and predicting prognosis of CRS. Among others, dry weight at hospital discharge is considered a surrogate marker of successful treatment in ADHF patients with/without renal dysfunction.
The etiology of WRF appears to be an important factor for determining risk related to WRF as well as clinical management. The hypertonic saline used as adjunctive therapy for intravenous loop diuretics and/or induction of aquaresis (e.g., using tolvaptan) may be promising and efficient approaches in the future.
KeywordsAcute decompensated heart failure Cardiorenal syndrome Cardiorenal interactions Tolvaptan Hypertonic saline solution Biomarkers
Compliance with Ethical Standards
Conflict of Interest
Agata Bielecka-Dabrowa, Breno Godoy, Joerg C. Schefold, Maciej Banach, and Stephan von Haehling each declare no potential conflicts of interest. Michael Koziolek reports a grant and personal fees from Novartis Pharma and personal fees from CVRx.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.CrossRefPubMedGoogle Scholar
- 5.• Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12:610–23. This review describes important crosstalk between the heart and kidney, with a focus on HF and kidney disease in the acute and chronic settings. CrossRefPubMedGoogle Scholar
- 6.McCullough PA: Cardiorenal syndromes: pathophysiology to prevention. Int J Nephrol 2011; 2011: 762590.Google Scholar
- 9.Roy AK, Mc Gorrian C, Treacy C, Kavanaugh E, Brennan A, Mahon NG, et al. A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. Cardiorenal Med. 2013;3:26–37.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–12.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Roy AK, Mc Gorrian C, Treacy C, Kavanaugh E, Brennan A, Mahon NG, et al. A comparison of traditional and novel definitions (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. Cardiorenal Med. 2013;3:26–37.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Park CS, Park JJ, Oh IY, Yoon CH, Choi DJ, Park HA, et al. Relation of renal function with left ventricular systolic function and NT-proBNP level and its prognostic implication in heart failure with preserved versus reduced ejection fraction: an analysis from the Korean Heart Failure (KorHF) registry. Korean Circ J. 2017;47:727–41.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Baydemir C, Ural D, Karaüzüm K, Balci S, Argan O, Karaüzüm I, et al. Predictors of long-term mortality and frequent re-hospitalization in patients with acute decompensated heart failure and kidney dysfunction treated with renin-angiotensin system blockers. Med Sci Monit. 2017;23:3335–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Qian JIA, Wang Y-R, Ping HE, Huang X-L, Yan W, Mu Y, et al. Prediction model of in-hospital mortality in elderly patients with acute heart failure based on retrospective study. J Geriatr Cardiol. 2017;14:669–78.Google Scholar
- 35.Ferreira JP, Chouihed T, Naseyrollas P, Levy B, Seronde MF, Bilbault P, et al. Practical management of concomitant acute heart failure and worsening renal function in the emergency department. Eur J Emerg Med. 2017 Oct 3:1. https://doi.org/10.1097/MEJ.0000000000000505.
- 36.Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Verdiani V, Tijssen JG, Pinto YM. Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure. JACC: HEART FAILURE 2015;3:751–61.Google Scholar
- 37.Grande D, Gioia MI, Terlizzese P, Iacoviello M. Heart failure and kidney disease. Adv Exp Med Biol. 2017; https://doi.org/10.1007/5584_2017_126.
- 38.Virzi GM, Clementi A, de Cal M, et al. Oxidative stress: dual pathway induction in cardiorenal syndrome type 1 pathogenesis. Oxidative Med Cell Longev. 2015:391790.Google Scholar
- 44.Shirakabe A, Hata N, Kobayashi N, Okazaki H, Matsushita M, Shibata Y, et al. Clinical usefulness of urinary liver fatty acid-binding protein excretion for predicting acute kidney injury during the first 7 days and the short-term prognosis in acute heart failure patients with non-chronic kidney disease. Cardiorenal Med. 2017;7(4):301–15.CrossRefPubMedGoogle Scholar
- 46.Dihazi H1, Koziolek MJ, Datta RR, Wallbach M, Jung K, Heise D, Dihazi GH, Markovic I, Asif AR, Müller GA. FABP1 and FABP3 have high predictive values for renal replacement therapy in patients with acute kidney injury. Blood Purif 2016;42(3):202–213.Google Scholar
- 48.Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation along with B-type Natriuretic peptide in acutely decompensated heart failure. (GALLANT) trial. Eur J Heart Fail. 2011;13:846–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Angeletti S, Fogolari M, Morolla D, Capone F, Costantino S, Spoto S, De Cesaris M, Lo Presti A, Ciccozzi M, Dicuonzo G. Role of neutrophil gelatinase-associated lipocalin in the diagnosis and early treatment of acute kidney injury in a case series of patients with acute decompensated heart failure: a case series. Cardiol Res Pract 2016;2016:3708210. doi: https://doi.org/10.1155/2016/3708210.
- 51.Damman K, Valente MAE, van Veldhuisen DJ, Cleland JGF, O’Connor CM, Metra PP, et al. Plasma neutrophil gelatinase-associated lipocalin and predicting clinically relevant worsening renal function in acute heart failure. Int J Mol Sci. 2017;18:1470. https://doi.org/10.3390/ijms18071470.CrossRefPubMedCentralGoogle Scholar
- 53.Nakada Y, Kawakami R, Matsui M, Ueda T, Nakano T, Takitsume A, Nakagawa H, Nishida T, Onoue K, Soeda T, Okayama S, Watanabe M, Kawata H, Okura H, Saito Y. Prognostic value of urinary neutrophil gelatinase-associated lipocalin on the first day of admission for adverse events in patients with acute decompensated heart failure. J Am Heart Assoc 2017;6(5). pii: e004582. doi: https://doi.org/10.1161/JAHA.116.004582.
- 59.Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant. 2009;24(6):1901–8.CrossRefPubMedGoogle Scholar
- 60.Konishi M, Ebner N, Springer J, Schefold JC, Doehner W, Dschietzig TB, Anker SD, von Haehling S. Impact of plasma kynurenine level on functional capacity and outcome in heart failure—results from studies investigating co-morbidities aggravating heart failure (SICA-HF). Circ J 2016;81(1):52–61.Google Scholar
- 66.Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145:459–66.CrossRefPubMedGoogle Scholar
- 68.Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure. a double-blind study J Am Coll Cardiol. 2005;45:1997–2003.CrossRefPubMedGoogle Scholar
- 70.Paterna S, Fasullo S, Parrinello G, Cannizzaro S, Basile I, Vitrano G, et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF study). Am J Med Sci. 2011;342:27–37.CrossRefPubMedGoogle Scholar
- 71.• De Vecchis R, Esposito C, Ariano C, Cantatrione S. Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: a meta-analysis of the literature. Herz 2015;40(3):423–35. This is a recent article that based on five randomized controlled trials involving 1,032 patients treated with i.v. HSS plus furosemide versus 1,032 patients treated with i.v. furosemide alone showed that HSS as an adjunct to i.v. furosemide for diuretic-resistant CHF patients led to a better renal safety profile and improved clinical endpoints such as mortality and heart failure-related hospitalizations. Google Scholar
- 76.Joannidis M, Druml W, Forni LG, Groeneveld ABJ, Honore PM, Hoste E, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: expert opinion of the working group on prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med. 2017;43(6):730–49.CrossRefPubMedPubMedCentralGoogle Scholar
- 79.Kitai T, Grodin JL, Kim YH, Tang WH. Impact of ultrafiltration on serum sodium homeostasis and its clinical implication in patients with acute heart failure, congestion, and worsening renal function. Circ Heart Fail. 2017;10(2):e003603. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003603. CrossRefPubMedPubMedCentralGoogle Scholar
- 80.Correa A, Patel A, Chauhan K, Shah H, Saha A, Dave M, Poojary P, Mishra A, Annapureddy N, Dalal S, Konstantinidis I, Nimma R, Agarwal SK, Chan L, Nadkarni G, Pinney S. National trends and outcomes in dialysis-requiring acute kidney injury in heart failure: 2002–2013. J Card Fail 2018 May 3. pii: S1071-9164(18)30170-2. https://doi.org/10.1016/j.cardfail.2018.05.001. [Epub ahead of print].
- 84.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, AJS C, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.CrossRefPubMedGoogle Scholar
- 87.Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007 28;297(12):1332–1343.Google Scholar
- 90.Kato M, Tohyama K, Ohya T, Hiro T, Hirayama A. Association between plasma concentration of tolvaptan and urine volume in acute decompensated heart failure patients with fluid overload. Cardiol J. 2016;23:497–504.Google Scholar
- 91.Nakano Y, Mizuno T, Niwa T, Mukai K, Wakabayashi H, Watanabe A, et al. Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease. Int Heart J [Internet]. 2018 [cited 2018 Jan 22]; Available from: https://www.jstage.jst.go.jp/article/ihj/advpub/0/advpub_16-625/_article.
- 93.Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction—prospective randomized controlled study. Circ J. 2017;81(5):740–7.CrossRefPubMedGoogle Scholar
- 94.Ellison DH, Felker GM. Diuretic treatment in heart failure. Ingelfinger JR, editor. N Engl J Med 2017;377:1964–1975.Google Scholar
- 98.•• Wang C, Xiong B, Cai L. Effects of tolvaptan in patients with acute heart failure: a systematic review and meta-analysis. BMC CardiovascDisord [Internet]. 2017 Dec [cited 2018 Jan 22];17(1). Available from: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-017-0598-y This is the most recent meta-analysis assessing the role of tolvaptan in a total of 746 patients with acute heart failure. The study revealed that tolvaptan can decrease body weight, increase serum sodium level, and ameliorate some of the congestion symptoms in patients with acute heart failure, which may help avoid the overdose of loop diuretics, especially in patients with renal dysfunction.
- 99.Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. RELAXin in acute heart failure (RELAX-AHF) investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;81(9860):29–39.CrossRefGoogle Scholar
- 101.Metra M1, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR; RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61(2):196–206.Google Scholar
- 102.Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, et al. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant. 2016;31(2):255–61.PubMedGoogle Scholar
- 103.Cohn JN1, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325(5):303–10.Google Scholar